LabGenomics Co., Ltd.
Financials
Valuation Metrics
LabGenomics Co., Ltd.'s Market Cap is ₩371B. At end of 2025 it was ₩1344B. Ranked #1951 of 2,421 in KR market (top 81%), #1226 of 1,640 on KOSDAQ (top 75%), #207 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 90%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 37.12B KRW | KR#1,951/2,421 Sec#207/231 |
| Revenue | 77.64B KRW | KR#1,563/2,421 Sec#99/231 |
| Net Income | -51.60B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 232.08B KRW | KR#1,204/2,421 Sec#85/231 |
| Net Assets | 147.96B KRW | KR#1,144/2,421 Sec#80/231 |
| Employees | 186 | KR#1,149/2,421 Sec#96/231 |
| Value | ||
| P/B | 0.25x | KR#216/2,421 Sec#6/231 |
| P/S | 0.48x | KR#894/2,421 Sec#41/231 |
| FCF Yield | -85.33% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -34.87% | KR#2,218/2,421 Sec#187/231 |
| ROA | -22.23% | KR#2,261/2,421 Sec#181/231 |
| Op. Margin | -49.82% | KR#2,236/2,421 Sec#161/231 |
| Revenue Growth | -11.73% | KR#1,961/2,421 Sec#180/231 |
| Financial Health | ||
| Debt Ratio | 56.85% | KR#1,056/2,421 Sec#122/231 |
| FCF | -31.67B KRW | KR#2,003/2,421 Sec#193/231 |
| Cash | 9.35B KRW | KR#1,733/2,421 Sec#147/231 |
| Current Ratio | 1.00x | KR#1,727/2,421 Sec#173/231 |
| Performance | ||
| 1Y Return | -78.02% | KR—/2,421 Sec—/231 |
| 1M Return | -8.59% | KR—/2,421 Sec—/231 |
| From 52W High | -80.35% | KR#2,347/2,421 Sec#219/231 |
| 1Y MDD | -80.04% | KR#2,295/2,421 Sec#207/231 |
| Trading | ||
| Volume | 1,889,637 shares | KR—/2,421 Sec—/231 |
| Trading Value | 973.5M KRW | KR—/2,421 Sec—/231 |
| Foreign Own. | 1.54% | KR#1,816/2,421 Sec#178/231 |
| Per Share | ||
| EPS | -695 KRW | KR—/2,421 Sec—/231 |
| BPS | 1,993 KRW | KR#2,070/2,421 Sec#173/231 |
Company Info
Labgenomics, established in 2002 as a specialized genomics molecular diagnostics company and headquartered in Seongnam-si, Gyeonggi-do, was listed on KOSDAQ in 2014. In 2024, the company officially entered the American diagnostic market by acquiring U.S. CLIA labs QDx Pathology Services and IMD, securing a diagnostic service network across the United States. It operates various genomics molecular diagnostics businesses, having commercialized Korea's first Next-Generation Sequencing (NGS)-based non-invasive prenatal testing for fetal abnormalities and established a network of over 3,000 hospitals nationwide.